Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 21,200 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Active, not recruiting Phase 2 Interventional Results available

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04665765
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
Carboplatin, Etoposide, Ifosfamide, Polatuzumab Vedotin, Rituximab
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Duarte, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 1:30 AM EDT
Active, not recruiting Not applicable Interventional

Clinic-level Implementation of mHealth to Improve HIV Viral Suppression for Patients With Substance Use Disorders

NCT06109571
View directory record Official record
Conditions
HIV Infections, Substance Use Disorders
Interventions
Connections App
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Denver, Colorado • Kansas City, Missouri • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 1:30 AM EDT
Completed No phase listed Observational

SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease

NCT00002563
View directory record Official record
Conditions
Lymphoma, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2005
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Worcester, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 23, 2026, 1:30 AM EDT
Terminated Phase 3 Interventional Results available

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

NCT04549363
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Westwood, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 23, 2026, 1:30 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Project Minority AIDS Prevention: Reaching Black and Hispanic MSM About PrEP and TasP Using Social Media

NCT03404531
View directory record Official record
Conditions
HIV Infections
Interventions
Social Media Messages Intervention Group, Website Only Group
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 23, 2026, 1:30 AM EDT
Not listed No phase listed Observational

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

NCT03551002
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 23, 2026, 1:30 AM EDT
Terminated No phase listed Observational

Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA

NCT01720745
View directory record Official record
Conditions
Cancer, Infection, Inflammation, Tumor, Sarcoid, Lymphadenopathy, Lymphoma
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Minneapolis, Minnesota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 23, 2026, 1:30 AM EDT
Completed Phase 1 Interventional

Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

NCT02593045
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
IPH4102
Biological
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Stanford, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 23, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 23, 2026, 1:30 AM EDT
Active, not recruiting Phase 1 Interventional

An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

NCT04590872
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Tolerogenic Dendritic Cell Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 1:30 AM EDT
Completed No phase listed Observational

Collection of Blood Samples From HIV Infected People

NCT00096772
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
83
States / cities
Mill Valley, California • Oakland, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 23, 2026, 1:30 AM EDT
Completed Phase 1 Interventional

Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability

NCT00242177
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
ACTOS (Pioglitazone)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 23, 2026, 1:30 AM EDT
Not listed Phase 1 Interventional

Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

NCT04559412
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sofusa DoseConnect, Enbrel
Device · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 23, 2026, 1:30 AM EDT
Terminated Phase 1 Interventional

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

NCT04070781
View directory record Official record
Conditions
Steroid Refractory GVHD, Graft Vs Host Disease
Interventions
Itacitinib, Tocilizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 23, 2026, 1:30 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Beetroot Juice NO Cold Study

NCT06416228
View directory record Official record
Conditions
Respiratory Tract Infections, Cold Symptoms, Exhaled Nitric Oxide
Interventions
Beetroot juice
Dietary Supplement
Lead sponsor
Southern Methodist University
Other
Eligibility
18 Years to 30 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Dallas, Texas • Waco, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 23, 2026, 1:30 AM EDT
Completed Not applicable Interventional Results available

Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes

NCT04540536
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Noncompliance, Patient
Interventions
Continuous Glucose Monitoring, Secure texting
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 23, 2026, 1:30 AM EDT
Not listed Phase 1Phase 2 Interventional

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

NCT00679536
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine, Thymoglobulin, Total Body Irradiation
Drug · Radiation
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Oct 23, 2026, 1:30 AM EDT
Completed Not applicable Interventional

ENLaCE Pilot Study

NCT01641211
View directory record Official record
Conditions
Asthma
Interventions
Meducation device technique video, Nutrition video
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 16 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Thomasville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 23, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871
View directory record Official record
Conditions
Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Interventions
branebrutinib, abatacept, branebrutinib placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Covina, California • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 23, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

NCT06090864
View directory record Official record
Conditions
Hodgkin Lymphoma, Relapse, Refractory
Interventions
Chemotherapy, Cell infusion
Drug · Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 1:30 AM EDT
Enrolling by invitation Not applicable Interventional

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

NCT06374264
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
MR-C-014
Device
Lead sponsor
MedRhythms, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 23, 2026, 1:30 AM EDT
Enrolling by invitation Not applicable Interventional

Impact of Integrated Pet Care on Glycemic Control and Diabetes Responsibility

NCT06598345
View directory record Official record
Conditions
Type 1 Diabetes Mellitis
Interventions
Routine Pet Fish Care, Collaborative Communication
Behavioral
Lead sponsor
Duke University
Other
Eligibility
10 Years to 13 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 1:30 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

NCT06851767
View directory record Official record
Conditions
X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions
Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells
Genetic · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 1:30 AM EDT
Completed Not applicable Interventional Results available

Bronchial Thermoplasty in Severe Persistent Asthma

NCT01350336
View directory record Official record
Conditions
Severe Asthma
Interventions
Alair System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
23
States / cities
Birmingham, Alabama • New Haven, Connecticut • Chicago, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 23, 2026, 1:30 AM EDT